Centessa Pharmaceuticals plc Share Option Transactions

On June 24, 2026, Centessa Pharmaceuticals plc (the "Company") was acquired by Eli Lilly and Company through a scheme of arrangement. As a result, all outstanding share options were cancelled and converted into the right to receive cash and contingent value rights (CVRs). Specifically, option holders received cash equal to the difference between $38.00 and the option's exercise price, plus one CVR per share, entitling them to potential future payments of up to $9.00 per share based on specified milestones. No options were exercised prior to the acquisition. Mathias Hukkelhoven, a director, was involved in these transactions, with his options being cancelled and converted as described. The filing details several share option transactions on June 24, 2026, including options with exercise prices ranging from $5.17 to $12.43, all of which were disposed of.